APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting PEG-rhG-CSF

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Long-acting PEG-rhG-CSF Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025198 pages

Choose your research edition.

Industry ResearchLong-acting PEG-rhG-CSF Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting PEG-rhG-CSF Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Long-acting PEG-rhG-CSF Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting PEG-rhG-CSF Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting PEG-rhG-CSF Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Long-acting PEG-rhG-CSF market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Long-acting PEG-rhG-CSF is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Long-acting PEG-rhG-CSF is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting PEG-rhG-CSF is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Long-acting PEG-rhG-CSF is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Long-acting PEG-rhG-CSF include CSPC, Sandoz (Novartis), Qilu Pharmaceutical, Mylan, Pfizer, Jiangsu Hengrui Medicine, Fresenius Kabi, Amgen Inc. and Coherus BioSciences, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Long-acting PEG-rhG-CSF market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Long-acting PEG-rhG-CSF and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Long-acting PEG-rhG-CSF sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Long-acting PEG-rhG-CSF market size, projected growth trends, production technologies, key applications, and end-use industries.

Long-acting PEG-rhG-CSF Segment by Company

CSPC

Sandoz (Novartis)

Qilu Pharmaceutical

Mylan

Pfizer

Jiangsu Hengrui Medicine

Fresenius Kabi

Amgen Inc.

Coherus BioSciences, Inc.

Biocon Biologics Inc.

Long-acting PEG-rhG-CSF Segment by Type

Innovative Drugs

Generic Drugs

Long-acting PEG-rhG-CSF Segment by Application

Blood Disorders

Neoplastic Diseases

Others

Long-acting PEG-rhG-CSF Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting PEG-rhG-CSF market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting PEG-rhG-CSF and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting PEG-rhG-CSF.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Long-acting PEG-rhG-CSF market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Long-acting PEG-rhG-CSF manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Long-acting PEG-rhG-CSF in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Long-acting PEG-rhG-CSF in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Long-acting PEG-rhG-CSF Industry Trends Table 2. Long-acting PEG-rhG-CSF Industry Drivers Table 3. Long-acting PEG-rhG-CSF Industry Opportunities and Challenges Table 4. Long-acting PEG-rhG-CSF Industry Restraints Table 5. Global Long-acting PEG-rhG-CSF Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Long-acting PEG-rhG-CSF Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Long-acting PEG-rhG-CSF Sales by Manufacturers (units) & (2021-2026) Table 8. Global Long-acting PEG-rhG-CSF Sales Market Share by Manufacturers Table 9. Global Long-acting PEG-rhG-CSF Average Sales Price (USD/unit) of Manufacturers (2021-2026) Table 10. Global Long-acting PEG-rhG-CSF Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Long-acting PEG-rhG-CSF Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Long-acting PEG-rhG-CSF Manufacturers, Product Type & Application Table 13. Global Long-acting PEG-rhG-CSF Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Long-acting PEG-rhG-CSF by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Innovative Drugs Table 17. Major Manufacturers of Generic Drugs Table 18. Global Long-acting PEG-rhG-CSF Sales by Type 2021 VS 2025 VS 2032 (units) Table 19. Global Long-acting PEG-rhG-CSF Sales by Type (2021-2026) & (units) Table 20. Global Long-acting PEG-rhG-CSF Sales by Type (2027-2032) & (units) Table 21. Global Long-acting PEG-rhG-CSF Sales Market Share by Type (2021-2026) Table 22. Global Long-acting PEG-rhG-CSF Sales Market Share by Type (2027-2032) Table 23. Global Long-acting PEG-rhG-CSF Revenue by Type 2021 VS 2025 VS 2032 (units) Table 24. Global Long-acting PEG-rhG-CSF Revenue by Type (2021-2026) & (units) Table 25. Global Long-acting PEG-rhG-CSF Revenue by Type (2027-2032) & (units) Table 26. Global Long-acting PEG-rhG-CSF Revenue Market Share by Type (2021-2026) Table 27. Global Long-acting PEG-rhG-CSF Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Blood Disorders Table 29. Major Manufacturers of Neoplastic Diseases Table 30. Major Manufacturers of Others Table 31. Global Long-acting PEG-rhG-CSF Sales by Application 2021 VS 2025 VS 2032 (units) Table 32. Global Long-acting PEG-rhG-CSF Sales by Application (2021-2026) & (units) Table 33. Global Long-acting PEG-rhG-CSF Sales by Application (2027-2032) & (units) Table 34. Global Long-acting PEG-rhG-CSF Sales Market Share by Application (2021-2026) Table 35. Global Long-acting PEG-rhG-CSF Sales Market Share by Application (2027-2032) Table 36. Global Long-acting PEG-rhG-CSF Revenue by Application 2021 VS 2025 VS 2032 (units) Table 37. Global Long-acting PEG-rhG-CSF Revenue by Application (2021-2026) & (units) Table 38. Global Long-acting PEG-rhG-CSF Revenue by Application (2027-2032) & (units) Table 39. Global Long-acting PEG-rhG-CSF Revenue Market Share by Application (2021-2026) Table 40. Global Long-acting PEG-rhG-CSF Revenue Market Share by Application (2027-2032) Table 41. Global Long-acting PEG-rhG-CSF Sales by Region: 2021 VS 2025 VS 2032 (units) Table 42. Global Long-acting PEG-rhG-CSF Sales by Region (2021-2026) & (units) Table 43. Global Long-acting PEG-rhG-CSF Sales Market Share by Region (2021-2026) Table 44. Global Long-acting PEG-rhG-CSF Sales Forecasted by Region (2027-2032) & (units) Table 45. Global Long-acting PEG-rhG-CSF Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Long-acting PEG-rhG-CSF Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (units) Table 47. North America Long-acting PEG-rhG-CSF Sales by Country (2021-2026) & (units) Table 48. North America Long-acting PEG-rhG-CSF Sales by Country (2027-2032) & (units) Table 49. Europe Long-acting PEG-rhG-CSF Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (units) Table 50. Europe Long-acting PEG-rhG-CSF Sales by Country (2021-2026) & (units) Table 51. Europe Long-acting PEG-rhG-CSF Sales by Country (2027-2032) & (units) Table 52. Asia Pacific Long-acting PEG-rhG-CSF Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (units) Table 53. Asia Pacific Long-acting PEG-rhG-CSF Sales by Country (2021-2026) & (units) Table 54. Asia Pacific Long-acting PEG-rhG-CSF Sales by Country (2027-2032) & (units) Table 55. South America, Middle East and Africa Long-acting PEG-rhG-CSF Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (units) Table 56. South America, Middle East and Africa Long-acting PEG-rhG-CSF Sales by Country (2021-2026) & (units) Table 57. South America, Middle East and Africa Long-acting PEG-rhG-CSF Sales by Country (2027-2032) & (units) Table 58. Global Long-acting PEG-rhG-CSF Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Long-acting PEG-rhG-CSF Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Long-acting PEG-rhG-CSF Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Long-acting PEG-rhG-CSF Revenue Market Share by Region (2021-2026) Table 62. Global Long-acting PEG-rhG-CSF Revenue Market Share by Region (2027-2032) Table 63. CSPC Company Information Table 64. CSPC Business Overview Table 65. CSPC Long-acting PEG-rhG-CSF Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. CSPC Long-acting PEG-rhG-CSF Product Portfolio Table 67. CSPC Recent Development Table 68. Sandoz (Novartis) Company Information Table 69. Sandoz (Novartis) Business Overview Table 70. Sandoz (Novartis) Long-acting PEG-rhG-CSF Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Sandoz (Novartis) Long-acting PEG-rhG-CSF Product Portfolio Table 72. Sandoz (Novartis) Recent Development Table 73. Qilu Pharmaceutical Company Information Table 74. Qilu Pharmaceutical Business Overview Table 75. Qilu Pharmaceutical Long-acting PEG-rhG-CSF Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Qilu Pharmaceutical Long-acting PEG-rhG-CSF Product Portfolio Table 77. Qilu Pharmaceutical Recent Development Table 78. Mylan Company Information Table 79. Mylan Business Overview Table 80. Mylan Long-acting PEG-rhG-CSF Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Mylan Long-acting PEG-rhG-CSF Product Portfolio Table 82. Mylan Recent Development Table 83. Pfizer Company Information Table 84. Pfizer Business Overview Table 85. Pfizer Long-acting PEG-rhG-CSF Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Pfizer Long-acting PEG-rhG-CSF Product Portfolio Table 87. Pfizer Recent Development Table 88. Jiangsu Hengrui Medicine Company Information Table 89. Jiangsu Hengrui Medicine Business Overview Table 90. Jiangsu Hengrui Medicine Long-acting PEG-rhG-CSF Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Jiangsu Hengrui Medicine Long-acting PEG-rhG-CSF Product Portfolio Table 92. Jiangsu Hengrui Medicine Recent Development Table 93. Fresenius Kabi Company Information Table 94. Fresenius Kabi Business Overview Table 95. Fresenius Kabi Long-acting PEG-rhG-CSF Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Fresenius Kabi Long-acting PEG-rhG-CSF Product Portfolio Table 97. Fresenius Kabi Recent Development Table 98. Amgen Inc. Company Information Table 99. Amgen Inc. Business Overview Table 100. Amgen Inc. Long-acting PEG-rhG-CSF Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Amgen Inc. Long-acting PEG-rhG-CSF Product Portfolio Table 102. Amgen Inc. Recent Development Table 103. Coherus BioSciences, Inc. Company Information Table 104. Coherus BioSciences, Inc. Business Overview Table 105. Coherus BioSciences, Inc. Long-acting PEG-rhG-CSF Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Coherus BioSciences, Inc. Long-acting PEG-rhG-CSF Product Portfolio Table 107. Coherus BioSciences, Inc. Recent Development Table 108. Biocon Biologics Inc. Company Information Table 109. Biocon Biologics Inc. Business Overview Table 110. Biocon Biologics Inc. Long-acting PEG-rhG-CSF Sales (units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Biocon Biologics Inc. Long-acting PEG-rhG-CSF Product Portfolio Table 112. Biocon Biologics Inc. Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Long-acting PEG-rhG-CSF Distributors List Table 116. Long-acting PEG-rhG-CSF Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Long-acting PEG-rhG-CSF Product Image Figure 2. Global Long-acting PEG-rhG-CSF Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting PEG-rhG-CSF Market Size (2021-2032) & (US$ Million) Figure 4. Global Long-acting PEG-rhG-CSF Sales (2021-2032) & (units) Figure 5. Global Long-acting PEG-rhG-CSF Average Price (USD/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Long-acting PEG-rhG-CSF Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Innovative Drugs Image Figure 9. Generic Drugs Image Figure 10. Global Long-acting PEG-rhG-CSF Sales by Type (2021 VS 2025 VS 2032) & (units) Figure 11. Global Long-acting PEG-rhG-CSF Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Long-acting PEG-rhG-CSF Sales Market Share by Type (2021-2032) Figure 13. Global Long-acting PEG-rhG-CSF Revenue by Type (2021 VS 2025 VS 2032) & (units) Figure 14. Global Long-acting PEG-rhG-CSF Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Long-acting PEG-rhG-CSF Revenue Market Share by Type (2021-2032) Figure 16. Blood Disorders Image Figure 17. Neoplastic Diseases Image Figure 18. Others Image Figure 19. Global Long-acting PEG-rhG-CSF Sales by Application (2021 VS 2025 VS 2032) & (units) Figure 20. Global Long-acting PEG-rhG-CSF Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Long-acting PEG-rhG-CSF Sales Market Share by Application (2021-2032) Figure 22. Global Long-acting PEG-rhG-CSF Revenue by Application (2021 VS 2025 VS 2032) & (units) Figure 23. Global Long-acting PEG-rhG-CSF Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Long-acting PEG-rhG-CSF Revenue Market Share by Application (2021-2032) Figure 25. North America Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 26. North America Long-acting PEG-rhG-CSF Sales Market Share by Country (2021-2032) Figure 27. U.S. Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 28. Canada Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 29. Mexico Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 30. Europe Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 31. Europe Long-acting PEG-rhG-CSF Sales Market Share by Country (2021-2032) Figure 32. Germany Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 33. France Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 34. U.K. Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 35. Italy Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 36. Netherlands Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 37. Asia Pacific Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 38. Asia Pacific Long-acting PEG-rhG-CSF Sales Market Share by Country (2021-2032) Figure 39. China Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 40. Japan Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 41. South Korea Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 42. Southeast Asia Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 43. India Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 44. Australia Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 45. South America, Middle East and Africa Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 46. South America, Middle East and Africa Long-acting PEG-rhG-CSF Sales Market Share by Country (2021-2032) Figure 47. Brazil Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 48. South Africa Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 49. Saudi Arabia Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 50. Turkey Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 51. Argentina Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 52. UAE Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 53. Egypt Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 54. Chile Long-acting PEG-rhG-CSF Sales and Growth Rate (2021-2032) & (units) Figure 55. Global Long-acting PEG-rhG-CSF Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Long-acting PEG-rhG-CSF Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Figure 58. North America Long-acting PEG-rhG-CSF Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Figure 60. Europe Long-acting PEG-rhG-CSF Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Long-acting PEG-rhG-CSF Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Long-acting PEG-rhG-CSF Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Long-acting PEG-rhG-CSF Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Long-acting PEG-rhG-CSF Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Long-acting PEG-rhG-CSF Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Innovative Drugs
  • Generic Drugs
Applications
  • Blood Disorders
  • Neoplastic Diseases
  • Others
Companies covered
  • CSPC
  • Sandoz (Novartis)
  • Qilu Pharmaceutical
  • Mylan
  • Pfizer
  • Jiangsu Hengrui Medicine
  • Fresenius Kabi
  • Amgen Inc.
  • Coherus BioSciences, Inc.
  • Biocon Biologics Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Long-acting PEG-rhG-CSF Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Long-acting PEG-rhG-CSF Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Long-acting PEG-rhG-CSF Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Long-acting PEG-rhG-CSF Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Long-acting PEG-rhG-CSF Market Dynamics
  1. 2.1 Long-acting PEG-rhG-CSF Industry Trends
  2. 2.2 Long-acting PEG-rhG-CSF Industry Drivers
  3. 2.3 Long-acting PEG-rhG-CSF Industry Opportunities and Challenges
  4. 2.4 Long-acting PEG-rhG-CSF Industry Restraints
3 Long-acting PEG-rhG-CSF Market by Manufacturers
  1. 3.1 Global Long-acting PEG-rhG-CSF Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Long-acting PEG-rhG-CSF Sales by Manufacturers (2021-2026)
  3. 3.3 Global Long-acting PEG-rhG-CSF Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Long-acting PEG-rhG-CSF Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Long-acting PEG-rhG-CSF Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Long-acting PEG-rhG-CSF Manufacturers, Product Type & Application
  7. 3.7 Global Long-acting PEG-rhG-CSF Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Long-acting PEG-rhG-CSF Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Long-acting PEG-rhG-CSF Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Long-acting PEG-rhG-CSF Tier 1, Tier 2, and Tier 3
4 Long-acting PEG-rhG-CSF Market by Type
  1. 4.1 Long-acting PEG-rhG-CSF Type Introduction
  2. 4.1.1 Innovative Drugs
  3. 4.1.2 Generic Drugs
  4. 4.2 Global Long-acting PEG-rhG-CSF Sales by Type
  5. 4.2.1 Global Long-acting PEG-rhG-CSF Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Long-acting PEG-rhG-CSF Sales by Type (2021-2032)
  7. 4.2.3 Global Long-acting PEG-rhG-CSF Sales Market Share by Type (2021-2032)
  8. 4.3 Global Long-acting PEG-rhG-CSF Revenue by Type
  9. 4.3.1 Global Long-acting PEG-rhG-CSF Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Long-acting PEG-rhG-CSF Revenue by Type (2021-2032)
  11. 4.3.3 Global Long-acting PEG-rhG-CSF Revenue Market Share by Type (2021-2032)
5 Long-acting PEG-rhG-CSF Market by Application
  1. 5.1 Long-acting PEG-rhG-CSF Application Introduction
  2. 5.1.1 Blood Disorders
  3. 5.1.2 Neoplastic Diseases
  4. 5.1.3 Others
  5. 5.2 Global Long-acting PEG-rhG-CSF Sales by Application
  6. 5.2.1 Global Long-acting PEG-rhG-CSF Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Long-acting PEG-rhG-CSF Sales by Application (2021-2032)
  8. 5.2.3 Global Long-acting PEG-rhG-CSF Sales Market Share by Application (2021-2032)
  9. 5.3 Global Long-acting PEG-rhG-CSF Revenue by Application
  10. 5.3.1 Global Long-acting PEG-rhG-CSF Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Long-acting PEG-rhG-CSF Revenue by Application (2021-2032)
  12. 5.3.3 Global Long-acting PEG-rhG-CSF Revenue Market Share by Application (2021-2032)
6 Global Long-acting PEG-rhG-CSF Sales by Region
  1. 6.1 Global Long-acting PEG-rhG-CSF Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Long-acting PEG-rhG-CSF Sales by Region (2021-2032)
  3. 6.2.1 Global Long-acting PEG-rhG-CSF Sales by Region (2021-2026)
  4. 6.2.2 Global Long-acting PEG-rhG-CSF Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Long-acting PEG-rhG-CSF Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Long-acting PEG-rhG-CSF Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Long-acting PEG-rhG-CSF Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Long-acting PEG-rhG-CSF Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Long-acting PEG-rhG-CSF Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Long-acting PEG-rhG-CSF Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Long-acting PEG-rhG-CSF Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Long-acting PEG-rhG-CSF Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Long-acting PEG-rhG-CSF Revenue by Region
  1. 7.1 Global Long-acting PEG-rhG-CSF Revenue by Region
  2. 7.1.1 Global Long-acting PEG-rhG-CSF Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Long-acting PEG-rhG-CSF Revenue by Region (2021-2026)
  4. 7.1.3 Global Long-acting PEG-rhG-CSF Revenue by Region (2027-2032)
  5. 7.1.4 Global Long-acting PEG-rhG-CSF Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Long-acting PEG-rhG-CSF Revenue (2021-2032)
  8. 7.2.2 North America Long-acting PEG-rhG-CSF Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Long-acting PEG-rhG-CSF Revenue (2021-2032)
  11. 7.3.2 Europe Long-acting PEG-rhG-CSF Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Long-acting PEG-rhG-CSF Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Long-acting PEG-rhG-CSF Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Long-acting PEG-rhG-CSF Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Long-acting PEG-rhG-CSF Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 CSPC
  2. 8.1.1 CSPC Company Information
  3. 8.1.2 CSPC Business Overview
  4. 8.1.3 CSPC Long-acting PEG-rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 CSPC Long-acting PEG-rhG-CSF Product Portfolio
  6. 8.1.5 CSPC Recent Developments
  7. 8.2 Sandoz (Novartis)
  8. 8.2.1 Sandoz (Novartis) Company Information
  9. 8.2.2 Sandoz (Novartis) Business Overview
  10. 8.2.3 Sandoz (Novartis) Long-acting PEG-rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sandoz (Novartis) Long-acting PEG-rhG-CSF Product Portfolio
  12. 8.2.5 Sandoz (Novartis) Recent Developments
  13. 8.3 Qilu Pharmaceutical
  14. 8.3.1 Qilu Pharmaceutical Company Information
  15. 8.3.2 Qilu Pharmaceutical Business Overview
  16. 8.3.3 Qilu Pharmaceutical Long-acting PEG-rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Qilu Pharmaceutical Long-acting PEG-rhG-CSF Product Portfolio
  18. 8.3.5 Qilu Pharmaceutical Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Long-acting PEG-rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Long-acting PEG-rhG-CSF Product Portfolio
  24. 8.4.5 Mylan Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Long-acting PEG-rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Long-acting PEG-rhG-CSF Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Jiangsu Hengrui Medicine
  32. 8.6.1 Jiangsu Hengrui Medicine Company Information
  33. 8.6.2 Jiangsu Hengrui Medicine Business Overview
  34. 8.6.3 Jiangsu Hengrui Medicine Long-acting PEG-rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Jiangsu Hengrui Medicine Long-acting PEG-rhG-CSF Product Portfolio
  36. 8.6.5 Jiangsu Hengrui Medicine Recent Developments
  37. 8.7 Fresenius Kabi
  38. 8.7.1 Fresenius Kabi Company Information
  39. 8.7.2 Fresenius Kabi Business Overview
  40. 8.7.3 Fresenius Kabi Long-acting PEG-rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Fresenius Kabi Long-acting PEG-rhG-CSF Product Portfolio
  42. 8.7.5 Fresenius Kabi Recent Developments
  43. 8.8 Amgen Inc.
  44. 8.8.1 Amgen Inc. Company Information
  45. 8.8.2 Amgen Inc. Business Overview
  46. 8.8.3 Amgen Inc. Long-acting PEG-rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Amgen Inc. Long-acting PEG-rhG-CSF Product Portfolio
  48. 8.8.5 Amgen Inc. Recent Developments
  49. 8.9 Coherus BioSciences, Inc.
  50. 8.9.1 Coherus BioSciences, Inc. Company Information
  51. 8.9.2 Coherus BioSciences, Inc. Business Overview
  52. 8.9.3 Coherus BioSciences, Inc. Long-acting PEG-rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Coherus BioSciences, Inc. Long-acting PEG-rhG-CSF Product Portfolio
  54. 8.9.5 Coherus BioSciences, Inc. Recent Developments
  55. 8.10 Biocon Biologics Inc.
  56. 8.10.1 Biocon Biologics Inc. Company Information
  57. 8.10.2 Biocon Biologics Inc. Business Overview
  58. 8.10.3 Biocon Biologics Inc. Long-acting PEG-rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Biocon Biologics Inc. Long-acting PEG-rhG-CSF Product Portfolio
  60. 8.10.5 Biocon Biologics Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Long-acting PEG-rhG-CSF Value Chain Analysis
  2. 9.1.1 Long-acting PEG-rhG-CSF Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Long-acting PEG-rhG-CSF Production Mode & Process
  6. 9.2 Long-acting PEG-rhG-CSF Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Long-acting PEG-rhG-CSF Distributors
  9. 9.2.3 Long-acting PEG-rhG-CSF Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst